Proceed with caution on new MS treatment
“There are a lot of people out there that have illnesses that are difficult to treat, impossible to cure,” Paul Hébert, editor-in-chief of the journal and co-author of the editorial, said in an interview. “The difficulty we now have is picking priorities.”
Bowing to pressure to allow widespread public access to the procedure before it’s been proven safe and effective in rigorous scientific trials could endanger patients and also create an expectation for a similar response each time a promising new treatment or procedure emerges, the editorial says.
At the same time, it’s unfair to completely block all patients from receiving the treatment they want, it says.